NC-B8

N/A

Report date: 2024/11/15 11:25:28

Base Information

Drug NameNC-B8
Drug Alias NameNC-B8
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitors
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsAmyotrophic Lateral SclerosisAlzheimer DiseaseParkinson Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEncefa
China Registration ClassN/A

Develop Information

Active CompaniesEncefa
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisAlzheimer DiseaseParkinson Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A